Peptides8 min read
IGF-1 LR3 and low blood sugar: what the evidence supports
Glucose lowering is a credible LR3 hazard, but animal experiments and related medicines do not define a safe human schedule.
Read articleBlog
Research, explained. Explore peptides, supplements, hormone health, longevity and red light therapy with clear, practical breakdowns of what the studies actually tell us.
Explore the articles
Find a topic you’re curious about and take a closer look.
Peptides8 min read
DSIP for withdrawal symptoms: why this is not an insomnia treatment claim
The historical DSIP withdrawal studies measured a different problem from chronic insomnia, with important gaps in comparison groups and follow-up.
Read article
Supplements9 min read
Inulin fiber: why the label cannot predict your gut response
Inulin may improve bowel frequency, but preparation, dose, diet, and gas symptoms matter. Learn how to compare labels with human studies.
Read article
Peptides9 min read
MOTS-c and CB4211: two names that should not share one evidence column
CB4211 produced exploratory human biomarker findings, but it is a MOTS-c analogue with its own formulation history. Its trial cannot validate native MOTS-c.
Read article
Peptides9 min read
SS-31 and primary mitochondrial disease: why diagnosis changes applicability
Elamipretide's myopathy trials, genetic subgroup findings and Barth syndrome approval answer different questions. Diagnosis determines how the evidence applies.
Read article
Peptides9 min read
Epitalon versus epithalamin: why the name changes the evidence
Why older epithalamin longevity reports cannot be treated as trials of synthetic Epitalon, and what the cell and animal research actually adds.
Read article
Peptides9 min read
Eloralintide and nausea: what receptor selectivity can—and can't—tell us
Early nausea rates were low, but the larger trial showed substantial variation. Receptor selectivity is only one possible part of the explanation.
Read article
Peptides9 min read
SS-31 and macular degeneration: what the eye trials actually found
Elamipretide eye trials separate visual performance from retinal imaging. Here is what ReCLAIM found, what it missed and what patients can ask.
Read article
Peptides9 min read
Kisspeptin and hormonal feedback: why more is not a simple equation
Kisspeptin can raise reproductive hormones, but timing, feedback and repeated exposure change the response. Human studies explain why more is not always more.
Read article
Peptides8 min read
Thymosin beta-4 after a heart attack: what animal and human studies show
Thymosin beta-4 has progressed from mouse heart-injury models to early human trials. The overall result and an early-treatment signal need separate interpretation.
Read article
Peptides9 min read
Visceral and subcutaneous fat: why the distinction matters
Visceral fat, subcutaneous fat, liver fat, and muscle fat are different measurements. Learn how anatomy changes the meaning of a treatment result.
Read article
Peptides8 min read
Exenatide for feline diabetes: what 40% versus 20% really showed
An early feline exenatide study found six remissions versus three. Its design, outcome definitions and safety findings explain why that was not proof of benefit.
Read article278–289 of 600 articles